Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease

American Journal Geriatric Pharmacotherapy

Volumn 6, Issue 2, 2008, Pages 49-60

  Silver, Marcia R ^a   Agarwal, Anil ^b   Krause, Michelle ^c   Lei, Lei ^d   Stehman Breen, Catherine ^d  

^a METROHEALTH MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d AMGEN INC   (United States)

Author keywords

anemia; chronic kidney disease; darbepoetin alfa; elderly; hemoglobin

Indexed keywords

HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; BLOOD PRESSURE; BLURRED VISION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMMUNITY LIVING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; GERIATRIC PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INJECTION SITE PAIN; IRON DEFICIENCY ANEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PIGMENTED NEVUS; POST HOC ANALYSIS; PRIORITY JOURNAL; PRURITUS; RESTLESS LEGS SYNDROME; SIDE EFFECT; UNITED STATES;

AGE FACTORS; AGED; ANEMIA; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; LONG-TERM CARE; MALE; MIDDLE AGED; RESIDENCE CHARACTERISTICS;

EID: 48149091219     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2008.05.002     Document Type: Article

References (45)

1. Astor B., Muntner P., Levin A., et al. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 162 (2002) 1401-1408
2. Li S., Foley R., and Collins A. Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. Int Urol Nephrol 37 (2005) 395-402
3. Holland D., and Lam M. Predictors of hospitalization and death among pre-dialysis patients: A retrospective cohort study. Nephrol Dial Transplant 15 (2000) 650-658
4. Perlman R., Finkelstein F., Liu L., et al. Quality of life in chronic kidney disease (CKD): A cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 45 (2005) 658-666
5. Tong E., and Nissenson A. Erythropoietin and anemia. Semin Nephrol 21 (2001) 190-203
6. Al-Ahmad A., Rand W., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 955-962
7. Fried L., Shlipak M., Crump C., et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 41 (2003) 1364-1372
8. Herzog C., Muster H., Li S., and Collins A. Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. J Card Fail 10 (2004) 467-472
9. Drüeke T., Locatelli F., Clyne N., et al., CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
10. Singh A., Szczech L., Tang K., et al., CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
11. Siamopoulos K., Gouva C., Katopodis K., et al. Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD. Am J Kidney Dis 48 (2006) 242-249
12. Fink J., Blahut S., Reddy M., and Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 37 (2001) 348-355
13. United States Renal Data System. USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States (2007), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md
14. Narayanan S., Critchlow C., Sciarra A., et al. Chronic kidney disease (CKD)-associated anemia is common in elderly nursing-home residents [abstract]. J Am Soc Nephrol 16 (2005) 549A
15. Egrie T., Dwyer E., Browne J., et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31 (2003) 290-299
16. Elliott S., Lorenzini T., Asher S., et al. Enhancement of therapeutic protein in in vivo activities through glycoengineering. Nat Biotechnol 21 (2003) 414-421
17. Hertel J., Locay H., Scarlata D., et al. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: Results from Simplify the Treatment of Anemia with Aranesp (STAAR). Am J Nephrol 26 (2006) 149-156
18. Hertel J., Locay H., Scarlata D., et al. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease. Mayo Clin Proc 81 (2006) 1188-1194
19. Suranyi M., Lindberg T., Navarro J., et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 23 (2003) 106-111
20. Toto R., Pichette V., Navarro J., et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 24 (2004) 453-460
21. Agarwal A., Silver M., Walczyk M., et al. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease. J Am Med Dir Assoc 8 (2007) 83-90
22. Agarwal A., Silver M., Reed T., et al. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med 260 (2006) 577-585
23. Ling B., Walczyk M., Agarwal A., et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 63 (2005) 327-334
24. Manjunath G., Sarnak M., and Levey A. Prediction equations to estimate glomerular filtration rate: An update. Curr Opin Nephrol Hypertens 10 (2001) 785-792
25. Blood studies: Hematology and coagulation. In: Fischbach F. (Ed). Manual of Laboratory and Diagnostic Tests. 4th ed. (2004), Lippincott Williams & Wilkins, Philadelphia, Pa 39-162
26. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39 Suppl 1 (2002) S1-S266
27. Hollander M., and Wolfe D. Nonparametric Statistical Methods (1973), John Wiley & Sons, New York, NY
28. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. [published correction appears in Am J Kidney Dis. 2001;38:442]. Am J Kidney Dis. 37 Suppl 1 (2001) S182-S238
29. Coresh J., Selvin E., Stevens L., et al. Prevalence of chronic kidney disease in the United States. JAMA 298 (2007) 2038-2047
30. Garg A., Papaioannou A., Ferko N., et al. Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int 65 (2004) 649-653
31. Robinson B., Artz A., Culleton B., et al. Prevalence of anemia in the nursing home: Contribution of chronic kidney disease. J Am Geriatr Soc 55 (2007) 1566-1570
32. Provenzano R., Garcia-Mayol L., Suchinda P., et al., POWER Study Group. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 61 (2004) 392-405
33. Revicki D., Brown R., Feeny D., et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25 (1995) 548-554
34. Rossert J., Levin A., Roger S., et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 47 (2006) 738-750
35. Abu-Alfa A., Hertel J., Locay H., et al. The effect of every-other-week (Q2W) darbepoetin alfa on hemoglobin (Hb) levels and health-related quality oflife (HRQoL) in older chronic kidney disease (CKD) patients naive to recombinant human erythropoietin (rHuEPO) [abstract]. J Am Geriatr Soc 54 (2006) B20
36. Gouva C., Nikolopoulos P., Ioannidis J., and Siamopoulos K. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int 66 (2004) 753-760
37. Jungers P., Choukroun G., Oualim Z., et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16 (2001) 307-312
38. Bernardo M., Crawford P., Hertel J., et al. Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting. J Manag Care Pharm 12 (2006) 714-725
39. Hertel J., Crawford P., Mafilios M., et al. Cost minimization model evaluating resource utilization to nephrology practices treating patients with erythropoietic stimulating protein (ESP) on a monthly (QM) versus weekly (QW) basis [abstract]. Am J Kidney Dis 47 (2006) A34
40. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 Update of hemoglobin target. Am J Kidney Dis. 50 (2007) 471-530
41. Mix T., Brenner R., Cooper M., et al. Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardio-vascular risk in patients with chronic kidney disease. [published correction appears in Am Heart J. 2005;150:53]. Am Heart J 149 (2005) 408-413
42. Hollowell J., van Assendelft O., Gunter E., et al., Centers for Disease Control and Prevention, National Center for Health Statistics. Hematological and iron-related analytes-reference data for persons aged 1 year and over: United States, 1988-94. Vital Health Stat 11 (2005) 1-156
43. Report of the WHO/UNICEF/UNU Consultation. Indicators and Strategies for Iron Deficiency and Anemia Programmes. Draft report, December 6-10,1993 (1994), World Health Organization, Geneva, Switzerland
44. Remuzzi G., and Ingelfinger J. Correction of anemia-payoffs and problems. N Engl J Med. 355 (2006) 2144-2146
45. Ng T., Marx G., Littlewood T., and Macdougall I. Recombinant erythropoietin in clinical practice. Postgrad Med J 79 (2003) 367-376